Condition: PTSD · Sponsor: Aptinyx
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Aptinyx Clinical Site | Tuscaloosa, Alabama, United States | — |
| Aptinyx Clinical Site | Phoenix, Arizona, United States | — |
| Aptinyx Clinical Site | Bentonville, Arkansas, United States | — |
| Aptinyx Clinical Site | Bellflower, California, United States | — |
| Aptinyx Clinical Site | Glendale, California, United States | — |
| Aptinyx Clinical Site | La Jolla, California, United States | — |
| Aptinyx Clinical Site | Oceanside, California, United States | — |
| Aptinyx Clinical Site | Riverside, California, United States | — |
| Aptinyx Clinical Site | Santa Ana, California, United States | — |
| Aptinyx Clinical Site | Temecula, California, United States | — |
| Aptinyx Clinical Site | Torrance, California, United States | — |
| Aptinyx Clinical Site | Colorado Springs, Colorado, United States | — |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05181995